Combination with ABT-199 has a synergistic effect, suggesting that mitochondrial Kv1.3 inhibitors could potentially be used as combination partner to venetoclax also in the treatment of t(11;14) negative multiple myeloma. This evidence concerns the gene KCNA3 and AL amyloidosis.